751 related articles for article (PubMed ID: 32816368)
1. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
2. Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells.
Somasagara RR; Deep G; Shrotriya S; Patel M; Agarwal C; Agarwal R
Int J Oncol; 2015 Apr; 46(4):1849-57. PubMed ID: 25672620
[TBL] [Abstract][Full Text] [Related]
3. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
5. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
6. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
7. Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells.
Dhar D; Deep G; Kumar S; Wempe MF; Raina K; Agarwal C; Agarwal R
Mol Carcinog; 2018 Sep; 57(9):1166-1180. PubMed ID: 29727019
[TBL] [Abstract][Full Text] [Related]
8. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
[TBL] [Abstract][Full Text] [Related]
9. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
[TBL] [Abstract][Full Text] [Related]
10. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
12. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
14. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
15. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
16. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
Wu P; Wang X; Ma Y; Xu X; Liu W; Sheng Z; Chen M; Zhou R; Zhang K; Goodin S; Zheng X; Li D
Bioorg Chem; 2020 Aug; 101():104022. PubMed ID: 32599367
[TBL] [Abstract][Full Text] [Related]
17. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
18. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
19. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
20. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]